Tag:

IPO

Latest Headlines

Latest Headlines

Report: Novo Nordisk to file for IT unit IPO in coming days

Novo Nordisk is reportedly set to unveil details of an IPO of its IT services business NNIT in the coming days. The Danish drugmaker has spent most of 2014 assessing whether to spin off the unit as an independent company.

UPDATED: Histogenics files for IPO, as Autogenomics refiles again

Implantable tissue repair player Histogenics has filed for an initial public offering to raise up to $65 million. The financing is to fund an ongoing Phase III trial for its NeoCart, an implant to repair knee cartilage damage. Meanwhile, Molecular diagnostics company AutoGenomics is hoping the third time's the charm with its IPO filing for up to $60 million.

MicroRNA company Microlin Bio withdraws IPO (again)

After two false starts in the summer, drug delivery company  Microlin  Bio is once again withdrawing its planned IPO due to unfavorable market conditions.  It had hoped to raise $28 million by offering 5.1 million shares on the Nasdaq priced between $4.50 and $5.50, Renaissance Capital reports.

Civitas, NeuroDerm, EyeGate to pursue IPO dreams, combined $165M on the line

Israel's NeuroDerm filed for a stock offering on the basis of its subcutaneous formulation for treating Parkinson's; Civitas, the developer of an inhaled formulation for the disease, is expected to debut on the Nasdaq Sept. 24; and EyeGate Pharmaceuticals, which employs low-voltage electrical current to deliver eye medication, also just filed for an IPO.

Intersect, Ocular ready to test the med tech IPO waters

A pair of med tech companies--Intersect ENT and Ocular Therapeutix--are on the road and ready for an IPO this week. Both of these companies have high-profile corporate investors, Medtronic and Baxter, respectively. They are trying to cash in on the recently renewed, public investor interest in life science IPOs to raise the money to market FDA-approved products and advance pipelines.

Why is there increased activity in animal health IPOs?

Husch Blackwell, a Kansas City, MO-based national legal firm with a Food & Agribusiness team, has laid out the top reasons behind the sudden rush--citing increased news coverage of the sector as one of them.

T2 Biosystems, bullish on new Candida Dx, files IPO plans

T2 Biosystems has filed plans for a proposed IPO worth as much as $69 million, a big advance for the Massachusetts in vitro diagnostics company.

MicroRNA delivery specialist Microlin Bio nears $30 million IPO

MicroLin Bio, a developer of microRNA treatments for cancer, is expected to price its $30 million IPO on the Nasdaq this week. Delays and share dilution have taken some of the shine off the event, but investors enthiusiam will ultimately hinge on the fate of its proprietary nanoparticle delivery technology.

$125M IPO planned for former BMS medical imaging unit

Avista Capital Partners is looking for liquidity in its investment in medical imaging agent provider Lantheus. The company recently filed for a $125 million IPO. The financing would allow Lantheus to repay some of the debt that the private equity firm loaded it up with, in part to pay itself dividends.

Newly public Inogen gains on FDA clearance for home oxygen device

Inogen is up almost 10% on news that it received FDA clearance for its latest home oxygen concentrator. Later this year, the company expects to start selling the device, which it has dubbed the Inogen At Home. It is up 32% since its February IPO.